Editorial Comment

Metformin has been proposed to have efficacy in prostate cancer through several putative mechanisms. They include effects on insulin responsive prostate cancers via attenuation of hyperinsulinemia, inhibition of oxidative phosphorylation causing energetic stress in cancer cells and potentially delaying the development of castrate resistant prostate cancer, which hyperinsulinemia can potentiate.1 Retrospective studies have supported the hypothesis that metformin can improve outcomes in patients with prostate cancer (reference 25 in article).
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Adult Urology Source Type: research